CIK 0001722964
YMAB Y-mAbs Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Sep 19, 2025.
Y-mAbs Therapeutics, Inc. (YMAB) has 21 SEC Form 4 filings on file from 12 insiders, the latest filed on Sep 19, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at YMAB. The newest: Thomas Gad (CHIEF BUSINESS OFFICER) sold $57k of stock on Mar 7, 2025, filed Mar 11, 2025, scored 22 (weak).
4 Form 144 notices of planned sales are on file, the latest filed Mar 7, 2025.
Last 90 days
Signals
Open-market buys and sells at Y-mAbs Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Thomas Gad CHIEF BUSINESS OFFICER sell | $57k 10,810 shares | -5% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 7, 2025 | Gad Thomas Officer, Director | 10,810 0.02% of outstanding | $57k | Mar 7, 2025 | none |
| Mar 7, 2025 | Rajah Vignesh Officer | 4,946 0.01% of outstanding | $26k | Mar 7, 2025 | none |
| Mar 7, 2025 | Rossi Michael J Officer, Director | 3,917 0.01% of outstanding | $20k | Mar 7, 2025 | none |
| Mar 7, 2025 | Smith Susan Laura Officer | 5,528 0.01% of outstanding | $29k | Mar 7, 2025 | none |
Transactions
The newest 50 of 118 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | Laura Hamill director | UTender of shares Common Stock | -5,825 | $8.60 | $50k | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -27,000 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -13,950 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,545 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | Laura Hamill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -33,450 | - | - | 0 | Sep 19, 2025 |
| Sep 16, 2025 | John LaRocca SVP, General Counsel & Secry | DDisposition to issuer Common Stock | -21,500 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Ashu Tyagi director | UTender of shares Common Stock | -5,825 | $8.60 | $50k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Michael J Rossi PRESIDENT & CEO | UTender of shares Common Stock | -7,982 | $8.60 | $69k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | James Healy director | UTender of shares Common Stock | -31,603 | $8.60 | $272k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Thomas Gad CHIEF BUSINESS OFFICER | UTender of shares Common Stock | -245,486 | $8.60 | $2.1M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Biotech ApS WG director, owner | UTender of shares Common Stock | -4,559,233 | $8.60 | $39M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | David N Gill director | DDisposition to issuer Common Stock | -5,825 | $8.60 | $50k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Peter P. Pfreundschuh EVP, CFO and Treasurer | DDisposition to issuer Common Stock | -77,800 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Douglas J Gentilcore SVP, Danyelza Bus. Unit Head | DDisposition to issuer Employee Stock Option (right to buy)derivative | -142,600 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Johan Wedell-Wedellsborg director, owner | UTender of shares Common Stock | -5,825 | $8.60 | $50k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Joris Wilms SVP & CHIEF OPERATING OFFICER | UTender of shares Common Stock | -12,799 | $8.60 | $110k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Johan Wedell-Wedellsborg director, owner | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | John LaRocca SVP, General Counsel & Secry | DDisposition to issuer Employee Stock Option (right to buy)derivative | -142,600 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Joris Wilms SVP & CHIEF OPERATING OFFICER | DDisposition to issuer Common Stock | -39,301 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Michael J Rossi PRESIDENT & CEO | DDisposition to issuer Common Stock | -129,101 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | David N Gill director | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Thomas Gad CHIEF BUSINESS OFFICER | DDisposition to issuer Common Stock | -60,235 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Ashu Tyagi director | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Peter P. Pfreundschuh EVP, CFO and Treasurer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -170,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | James Healy director | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | James Healy director | UTender of shares Common Stockindirect: See footnote | -2,194,278 | $8.60 | $19M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Ashu Tyagi director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Michael J Rossi PRESIDENT & CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -615,240 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Johan Wedell-Wedellsborg director, owner | UTender of shares Common Stockindirect: By WG Biotech ApS | -4,559,233 | $8.60 | $39M | 0 | Sep 18, 2025 |
| Sep 16, 2025 | John LaRocca SVP, General Counsel & Secry | DDisposition to issuer Employee Stock Option (right to buy)derivative | -42,900 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Peter P. Pfreundschuh EVP, CFO and Treasurer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -63,500 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Joris Wilms SVP & CHIEF OPERATING OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Thomas Gad CHIEF BUSINESS OFFICER | UTender of shares Common Stockindirect: By GAD Enterprises LLC | -67,681 | $8.60 | $582k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | David N Gill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -24,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Ashu Tyagi director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -32,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | James Healy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,222 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Peter P. Pfreundschuh EVP, CFO and Treasurer | DDisposition to issuer Restricted Stock Unitsderivative | -15,900 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Michael J Rossi PRESIDENT & CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -214,200 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | David N Gill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Joris Wilms SVP & CHIEF OPERATING OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Johan Wedell-Wedellsborg director, owner | DDisposition to issuer Employee Stock Option (right to buy)derivative | -36,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Thomas Gad CHIEF BUSINESS OFFICER | UTender of shares Common Stockindirect: By Children | -60,000 | $8.60 | $516k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | James Healy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -8,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Peter P. Pfreundschuh EVP, CFO and Treasurer | DDisposition to issuer Restricted Stock Unitsderivative | -15,900 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Michael J Rossi PRESIDENT & CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -210,700 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | David N Gill director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | Johan Wedell-Wedellsborg director, owner | DDisposition to issuer Employee Stock Option (right to buy)derivative | -32,000 | - | - | 0 | Sep 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- David N Gilldirector
- Thomas GadCHIEF BUSINESS OFFICER
- Douglas J GentilcoreSVP, Danyelza Bus. Unit Head
- James Healydirector
- Laura Hamilldirector
- John LaRoccaSVP, General Counsel & Secry
- Peter P. PfreundschuhEVP, CFO and Treasurer
- Michael J RossiPRESIDENT & CEO
- Ashu Tyagidirector
- Biotech ApS WGdirector, owner
- Johan Wedell-Wedellsborgdirector, owner
- Joris WilmsSVP & CHIEF OPERATING OFFICER
Questions about YMAB
Answered from the filings on this page, as of the latest one.
Are insiders buying YMAB?
No. In the last 90 days no insider at Y-mAbs Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade YMAB on the open market?
Thomas Gad (CHIEF BUSINESS OFFICER) sold $57k of YMAB on Mar 7, 2025 and filed the Form 4 on Mar 11, 2025. InsiderTell scored 22 (weak).
How many insiders file Form 4 at Y-mAbs Therapeutics, Inc.?
12 people have filed a Form 4 at Y-mAbs Therapeutics, Inc., among them David N Gill (director), Thomas Gad (CHIEF BUSINESS OFFICER), Douglas J Gentilcore (SVP, Danyelza Bus. Unit Head). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.